Progressive supranuclear palsy and corticobasal degeneration: novel clinical concepts and advances in biomarkers

ABSTRACT

Background: Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are sporadic adult-onset primary tauopathies clinically classified among the atypical parkinsonian syndromes. They are intrinsically related with regard to their clinical features, pathology, biochemistry, and genetic risk factors. Objectives: This review highlights the current knowledge on PSP and CBD, focusing on evolving clinical concepts, new diagnostic criteria, and advances in biomarkers. Methods: We performed a non-systematic literature review through the PubMed database. The search was restricted to articles written in English, published from 1964 to date. Results: Clinicopathologic and in vivo biomarkers studies have broadened PSP and CBD clinical phenotypes. They are now recognized as a range of motor and behavioral syndromes associated with underlying 4R-tauopathy neuropathology. The Movement Disorders Society PSP diagnostic criteria included clinical variants apart from the classical description, increasing diagnostic sensitivity. Meanwhile, imaging biomarkers have explored the complexity of symptoms and pathological processes related to corticobasal syndrome and CBD. Conclusions: In recent years, several prospective or clinicopathologic studies have assessed clinical, radiological, and fluid biomarkers that have helped us gain a better understanding of the complexity of the 4R-tauopathies, mainly PSP and CBD.

RESUMO

Antecedentes: A paralisia supranuclear progressiva (PSP) e a degeneração corticobasal (DCB) são taupatias esporádicas primárias clinicamente classificadas no grupo das síndromes parkinsonianas atípicas. Ambas estão intrinsecamente relacionadas no que concerne aos aspectos clínicos, patológicos, bioquímicos e genéticos.

Objetivos: Abordar os avanços recentes no conhecimento da PSP e DCB, focando na evolução dos conceitos clínicos, critérios diagnósticos, e avanços em biomarcadores. Métodos: Trata-se de uma revisão não-sistemática através da base de dados PubMed. Foram revisados artigos escritos em língua inglesa, publicados desde 1964 até a presente data. Resultados: Estudos com biomarcadores e análises postmortem ampliaram os fenótipos conhecidos da PSP e DCB. Tais doenças englobam um espectro amplo de síndromes motoras e cognitivas, associadas a neuropatologia tau com isoforma predominante 4R. O atual critério para PSP estabeleceu novas variantes clínicas para além da descrição clássica, aumentando a sensibilidade diagnóstica. Concomitantemente, biomarcadores in vivo exploraram a complexidade dos sintomas e processos patológicos relacionados à síndrome e degeneração corticobasal. Conclusões: Recentemente, alguns estudos prospectivos e clinicopatológicos investigaram aspectos clínicos, radiológicos e de biofluidos, que ajudaram a melhor compreender a heterogeneidade e complexidade clínica das taupatias 4R, sobretudo PSP e DCB.

Keywords:

Parkinsonian Disorders - Tauopathies - Supranuclear Palsy, Progressive - Positron-Emission Tomography - Magnetic Resonance Imaging - Biomarkers

Palavras-chave:

Transtornos Parkinsonianos - Tauopatias - Paralisia Supranuclear Progressiva - Tomografia por Emissão de Pósitrons - Imageamento por Ressonância Magnética - Biomarcadores

• Referências

• 1 Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, Basal Ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964; 10: 333-359 https://doi.org/10.1001/archneur.1964.00460160003001
• 2 Rebeiz JJ, Kolodny EH, Richardson Jr. EP. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans Am Neurol Assoc 1967; 92: 23-26
• 3 Rebeiz JJ, Kolodny EH, Richardson EP. Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 1968; 18 (01) 20-33 https://doi.org/10.1001/archneur.1968.00470310034003
• 4 Gibb WR, Luthert PJ, Marsden CD. Corticobasal degeneration. Brain 1989; 112 (05) 1171-1192 https://doi.org/10.1093/brain/112.5.1171
• 5 Ling H, O’Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR. et al. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain 2010; 133 (07) 2045-2057 https://doi.org/10.1093/brain/awq123
• 6 Horoupian DS, Wasserstein PH. Alzheimer’s disease pathology in motor cortex in dementia with Lewy bodies clinically mimicking corticobasal degeneration. Acta Neuropathol 1999; 98 (03) 317-322 https://doi.org/10.1007/s004010051087
• 7 Boeve BF, Maraganore DM, Parisi JE, Ahlskog JE, Graff-Radford N, Caselli RJ. et al. Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 1999; 53 (04) 795-800 https://doi.org/10.1212/wnl.53.4.795
• 8 Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003; Jun 23;54(5 Suppl 5): S15-S19 https://doi.org/10.1002/ana.10570
• 9 Ling H, Macerollo A. Is it useful to classify PSP and CBD as different disorders? Yes. Mov Disord Clin Pract 2018; 5 (02) 145-148 https://doi.org/10.1002/mdc3.12581
• 10 Stamelou M, Respondek G, Giagkou N, Whitwell JL, Kovacs GG, Höglinger GU. Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies. Nat Rev Neurol 2021; 17 (10) 601-620 https://doi.org/10.1038/s41582-021-00541-5
• 11 Respondek G, Kurz C, Arzberger T, Compta Y, Englund E, Ferguson LW. et al. Which ante mortem clinical features predict progressive supranuclear palsy pathology?. Mov Disord 2017; 32 (07) 995-1005 https://doi.org/10.1002/mds.27034
• 12 Coyle-Gilchrist IT, Dick KM, Patterson K, Vázquez Rodríquez P, Wehmann E, Wilcox A. et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 2016; 86 (18) 1736-1743 https://doi.org/10.1212/WNL.2022s1342022s1342638
• 13 Yoshida K, Hata Y, Kinoshita K, Takashima S, Tanaka K, Nishida N. Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes: a forensic autopsy series. Acta Neuropathol 2017; 133 (05) 809-823 https://doi.org/10.1007/s00401-016-1665-7
• 14 Takigawa H, Kitayama M, Wada-Isoe K, Kowa H, Nakashima K. Prevalence of progressive supranuclear palsy in Yonago: change throughout a decade. Brain Behav 2016; 6 (12) e00557 https://doi.org/10.1002/brb3.557
• 15 Togasaki DM, Tanner CM. Epidemiologic aspects. Adv Neurol 2000; 82: 53-59
• 16 Osaki Y, Morita Y, Kuwahara T, Miyano I, Doi Y. Prevalence of Parkinson’s disease and atypical parkinsonian syndromes in a rural Japanese district. Acta Neurol Scand 2011; 124 (03) 182-187 https://doi.org/10.1111/j.1600-0404.2010.01442.x
• 17 Winter Y, Bezdolnyy Y, Katunina E, Avakjan G, Reese JP, Klotsche J. et al. Incidence of Parkinson’s disease and atypical parkinsonism: Russian population-based study. Mov Disord 2010; 25 (03) 349-356 https://doi.org/10.1002/mds.22966
• 18 Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol 2017; 16 (07) P552-P563 https://doi.org/10.1016/S1474-4422(17)30157-6
• 19 Respondek G, Stamelou M, Kurz C, Ferguson LW, Rajput A, Chiu WZ. et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord 2014; 29 (14) 1758-1766 https://doi.org/10.1002/mds.26054
• 20 Williams DR, Holton JL, Strand C, Pittman A, Silva R, Lees AJ. et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson’s syndrome. Brain 2007; 130 (06) 1566-1576 https://doi.org/10.1093/brain/awm104
• 21 Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009; 8 (03) 270-279 https://doi.org/10.1016/S1474-4422(09)70042-0
• 22 Koga S, Josephs KA, Ogaki K, Labbé C, Uitti RJ, Graff-Radford N. et al. Cerebellar ataxia in progressive supranuclear palsy: an autopsy study of PSP-C. Mov Disord 2016; 31 (05) 653-662 https://doi.org/10.1002/mds.26499
• 23 Parmera JB, Rodriguez RD, Studart Neto A, Nitrini R, Brucki SMD. Corticobasal syndrome: a diagnostic conundrum. Dement Neuropsychol 2016; 10 (04) 267-275 https://doi.org/10.1590/s1980-5764-2016dn1004003
• 24 Lee SE, Rabinovici GD, Mayo MC, Wilson SM, Seeley WW, DeArmond SJ. et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol 2011; 70 (02) 327-340 https://doi.org/10.1002/ana.22424
• 25 Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B. et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013; 80 (05) 496-503 https://doi.org/10.1212/WNL.0b013e31827f0fd1
• 26 Mathew R, Bak TH, Hodges JR. Diagnostic criteria for corticobasal syndrome: a comparative study. J Neurol Neurosurg Psychiatry 2012; 83 (04) 405-410 https://doi.org/10.1136/jnnp-2011-300875
• 27 Kouri N, Whitwell JL, Josephs KA, Rademakers R, Dickson DW. Corticobasal degeneration: a pathologically distinct 4R tauopathy. Nat Rev Neurol 2011; 7 (05) 263-272 https://doi.org/10.1038/nrneurol.2011.43
• 28 Kouri N, Murray ME, Hassan A, Rademakers R, Uitti RJ, Boeve BF. et al. Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. Brain 2011; 134 (11) 3264-3275 https://doi.org/10.1093/brain/awr234
• 29 Bayram E, Dickson DW, Reich SG, Litvan I. Pathology-proven corticobasal degeneration presenting as Richardson’s syndrome. Mov Disord Clin Pract 2020; 7 (03) 267-272 https://doi.org/10.1002/mdc3.12900
• 30 Josephs KA, Duffy JR, Strand EA, Whitwell JL, Layton KF, Parisi JE. et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006; 129 (06) 1385-1398 https://doi.org/10.1093/brain/awl078
• 31 Höglinger GU. Is it useful to classify progressive supranuclear palsy and corticobasal degeneration as different disorders?. Mov Disord Clin Pract 2018; 5 (02) 141-144 https://doi.org/10.1002/mdc3.12582
• 32 Ghetti B, Oblak AL, Boeve BF, Johnson KA, Dickerson BC, Goedert M. Invited review: frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: a chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol 2015; 41 (01) 24-46 https://doi.org/10.1111/nan.12213
• 33 Kouri N, Ross OA, Dombroski B, Younkin CS, Serie DJ, Soto-Ortolaza A. et al. Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nat Commun 2015; 6: 7247 https://doi.org/10.1038/ncomms8247
• 34 Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE. et al. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 2017; 32 (06) 853-864 https://doi.org/10.1002/mds.26987
• 35 Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC. et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996; 47 (01) 1-9 https://doi.org/10.1212/wnl.47.1.1
• 36 Ali F, Martin PR, Botha H, Ahlskog JE, Bower JH, Masumoto JY. et al. Sensitivity and specificity of diagnostic criteria for progressive supranuclear palsy. Mov Disord 2019; 34 (08) 1144-1153 https://doi.org/10.1002/mds.27619
• 37 Saranza GM, Whitwell JL, Kovacs GG, Lang AE, Corticobasal degeneration. Stamelou M, Höglinger GU. International review of neurobiology. Elsevier Ltd: 2019: 87-136
• 38 Ouchi H, Toyoshima Y, Tada M, Oyake M, Aida I, Tomita I. et al. Pathology and sensitivity of current clinical criteria in corticobasal syndrome. Mov Disord 2014; 29 (02) 238-244 https://doi.org/10.1002/mds.25746
• 39 Alexander SK, Rittman T, Xuereb JH, Bak TH, Hodges JR, Rowe JB. Validation of the new consensus criteria for the diagnosis of corticobasal degeneration. J Neurol Neurosurg Psychiatry 2014; 85 (08) 925-929 https://doi.org/10.1136/jnnp-2013-307035
• 40 Respondek G, Grimm MJ, Piot I, Arzberger T, Compta Y, Englund E. et al. Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. Mov Disord 2020; 35 (01) 171-176 https://doi.org/10.1002/mds.27872
• 41 Kovacs GG. Invited review: neuropathology of tauopathies: principles and practice. Neuropathol Appl Neurobiol 2015; 41 (01) 3-23 https://doi.org/10.1111/nan.12208
• 42 Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol 2013; 12 (06) P609-P622 https://doi.org/10.1016/S1474-4422(13)70090-5
• 43 Clavaguera F, Grueninger F, Tolnay M. Intercellular transfer of tau aggregates and spreading of tau pathology: implications for therapeutic strategies. Neuropharmacology 2014; 76 A 9-15 https://doi.org/10.1016/j.neuropharm.2013.08.037
• 44 Höglinger GU, Litvan I, Mendonca N, Wang D, Zheng H, Rendenbach-Mueller B. et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol 2021; 20 (03) P182-P192 https://doi.org/10.1016/S1474-4422(20)30489-0
• 45 Kato N, Arai K, Hattori T. Study of the rostral midbrain atrophy in progressive supranuclear palsy. J Neurol Sci 2003; 210 1-2 57-60 https://doi.org/10.1016/s0022-510x(03)00014-5
• 46 Massey LA, Micallef C, Paviour DC, O’Sullivan SS, Ling H, Williams DR. et al. Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Mov Disord 2012; 27 (14) 1754-1762 https://doi.org/10.1002/mds.24968
• 47 Mueller C, Hussl A, Krismer F, Heim B, Mahlknecht P, Nocker M. et al. The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. Park Relat Disord 2018; 54: P90-P94 https://doi.org/10.1016/j.parkreldis.2018.04.005
• 48 Paviour DC, Price SL, Stevens JM, Lees AJ, Fox NC. Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology 2005; 64 (04) 675-679 https://doi.org/10.1212/01.WNL.0000151854.85743.C7
• 49 Whitwell JL, Höglinger GU, Antonini A, Bordelon Y, Boxer AL, Colosimo C. et al. Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be?. Mov Disord 2017; 32 (07) 955-971 https://doi.org/10.1002/mds.27038
• 50 Cosottini M, Ceravolo R, Faggioni L, Lazzarotti G, Michelassi MC, Bonuccelli U. et al. Assessment of midbrain atrophy in patients with progressive supranuclear palsy with routine magnetic resonance imaging. Acta Neurol Scand 2007; 116 (01) 37-42 https://doi.org/10.1111/j.1600-0404.2006.00767.x
• 51 Quattrone A, Nicoletti G, Messina D, Fera F, Condino F, Pugliese P. et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008; 246 (01) 214-221 https://doi.org/10.1148/radiol.2453061703
• 52 Nicoletti G, Tonon C, Lodi R, Condino F, Manners D, Malucelli E. et al. Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson’s disease. Mov Disord 2008; 23 (16) 2370-2376 https://doi.org/10.1002/mds.22279
• 53 Whitwell JL, Schwarz CG, Reid RI, Kantarci K, Jack Jr CR, Josephs KA. Diffusion tensor imaging comparison of progressive supranuclear palsy and corticobasal syndromes. Parkinsonism Relat Disord 2014; 20 (05) P493-P498 https://doi.org/10.1016/j.parkreldis.2014.01.023
• 54 Whitwell JL, Tosakulwong N, Botha H, Ali F, Clark HM, Duffy JR. et al. Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. Neuroimage Clin 2020; 25: 102152 https://doi.org/10.1016/j.nicl.2019.102152
• 55 Gardner RC, Boxer AL, Trujillo A, Mirsky JB, Guo CC, Gennatas ED. et al. Intrinsic connectivity network disruption in progressive supranuclear palsy. Ann Neurol 2013; 73 (05) 603-616 https://doi.org/10.1002/ana.23844
• 56 Rosskopf J, Gorges M, Müller HP, Lulé D, Uttner I, Ludolph AC. et al. Intrinsic functional connectivity alterations in progressive supranuclear palsy: Differential effects in frontal cortex, motor, and midbrain networks. Mov Disord 2017; 32 (07) 1006-1015 https://doi.org/10.1002/mds.27039
• 57 Lemos J, Pereira D, Almendra L, Rebelo D, Patrício M, Castelhano J. et al. Cortical control of vertical and horizontal saccades in progressive supranuclear palsy: an exploratory fMRI study. J Neurol Sci 2017; 373: 157-166 https://doi.org/10.1016/j.jns.2016.12.049
• 58 Sachin S, Kumaran SS, Singh S, Goyal V, Shukla G, Mahajan H. et al. Functional mapping in PD and PSP for sustained phonation and phoneme tasks. J Neurol Sci 2008; 273 1-2 51-56 https://doi.org/10.1016/j.jns.2008.06.024
• 59 Upadhyay N, Suppa A, Piattella MC, Di Stasio F, Petsas N, Colonnese C. et al. Gray and white matter structural changes in corticobasal syndrome. Neurobiol Aging 2016; 37: 82-90 https://doi.org/10.1016/j.neurobiolaging.2015.10.011
• 60 Whitwell JL, Jack Jr CR, Boeve BF, Parisi JE, Ahlskog JE, Drubach DA. et al. Imaging correlates of pathology in corticobasal syndrome. Neurology 2010; 75 (21) 1879-1887 https://doi.org/10.1212/WNL.0b013e3181feb2e8
• 61 Teune LK, Bartels AL, de Jong BM, Willemsen AT, Eshuis SA, de Vries JJ. et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord 2010; 25 (14) 2395-2404 https://doi.org/10.1002/mds.23291
• 62 Hellwig S, Amtage F, Kreft A, Buchert R, Winz OH, Vach W. et al. 18F#&093;FDG-PET is superior to #&091;123I IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012; 79 (13) 1314-1322 https://doi.org/10.1212/WNL.0b013e31826c1b0a
• 63 Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS. et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005; 26 (03) 912-921 https://doi.org/10.1016/j.neuroimage.2005.03.012
• 64 Niethammer M, Tang CC, Feigin A, Allen PJ, Heinen L, Hellwig S. et al. A disease-specific metabolic brain network associated with corticobasal degeneration. Brain 2014; 137 (11) 3036-3046 https://doi.org/10.1093/brain/awu256
• 65 Pardini M, Huey ED, Spina S, Kreisl WC, Morbelli S, Wassermann EM. et al. FDG-PET patterns associated with underlying pathology in corticobasal syndrome. Neurology 2019; 92 (10) e1121-e1135 https://doi.org/10.1212/WNL.2022s1342022s1347038
• 66 Parmera JB, Coutinho AM, Aranha MR, Studart-Neto A, de Godoi Carneiro C, de Almeida IJ. et al. FDG-PET Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome. Mov Disord 2021; 36 (03) 651-661 https://doi.org/10.1002/mds.28373
• 67 Parmera JB, de Almeida IJ, de Oliveira MCB, Silagi ML, de Godoi Carneiro C, Studart-Neto A. et al. Metabolic and structural signatures of speech and language impairment in corticobasal syndrome: a multimodal PET/MRI study. Front Neurol 2021; 12: 702052 https://doi.org/10.3389/fneur.2021.702052
• 68 Martí-Andrés G, van Bommel L, Meles SK, Riverol M, Valentí R, Kogan RV. et al. Multicenter Validation of Metabolic Abnormalities Related to PSP According to the MDS-PSP Criteria. Mov Disord 2020; 35 (11) 2009-2018 https://doi.org/10.1002/mds.28217
• 69 Josephs KA, Whitwell JL, Tacik P, Duffy JR, Senjem ML, Tosakulwong N. et al. 18F AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration. Acta Neuropathol 2016; 132 (06) 931-933 https://doi.org/10.1007/s00401-016-1618-1
• 70 Cho H, Choi JY, Hwang MS, Lee SH, Ryu YH, Lee MS. et al. Subcortical 18F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord 2017; 32 (01) 134-140 https://doi.org/10.1002/mds.26844
• 71 Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M. et al. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol 2020; 77 (11) 1408-1419 https://doi.org/10.1001/jamaneurol.2020.2526
• 72 Palleis C, Brendel M, Finze A, Weidinger E, Bötzel K, Danek A. et al. Cortical #&091;18F#&093; PI-2620 binding differentiates corticobasal syndrome subtypes. Mov Disord 2021; 36 (09) 2104-2115 https://doi.org/10.1002/mds.28624
• 73 Laforce Jr R, Soucy JP, Sellami L, Dallaire-Théroux C, Brunet F, Bergeron D. et al. Molecular imaging in dementia: past, present, and future. Alzheimers Dement 2018; 14 (11) 1522-1552 https://doi.org/10.1016/j.jalz.2018.06.2855
• 74 Burrell JR, Hornberger M, Villemagne VL, Rowe CC, Hodges JR. Clinical profile of PiB-positive corticobasal syndrome. PLoS One 2013; 8 (04) e61025 https://doi.org/10.1371/journal.pone.0061025
• 75 Blennow K, Zetterberg H. The past and the future of Alzheimer’s disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. Front Neurosci 2015; 9: 345 https://doi.org/10.3389/fnins.2015.00345
• 76 Magdalinou N, Lees AJ, Zetterberg H. Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry 2014; 85 (10) 1065-1075 https://doi.org/10.1136/jnnp-2013-307539
• 77 Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K. et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2015; 86 (11) 1240-1247 https://doi.org/10.1136/jnnp-2014-309562
• 78 Jabbari E, Zetterberg H, Morris HR. Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. J Neurol Neurosurg Psychiatry 2017; 88 (10) 883-888 https://doi.org/10.1136/jnnp-2017-315857
• 79 Rojas JC, Karydas A, Bang J, Tsai RM, Blennow K, Liman V. et al. Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 2016; 3 (03) 216-225 https://doi.org/10.1002/acn3.290
• 80 Boxer AL, Qureshi I, Ahlijanian M, Grundman M, Golbe LI, Litvan I. et al. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol 2019; 18 (06) P549-P558 https://doi.org/10.1016/S1474-4422(19)30139-5